Program
Human Growth Hormone
Also written as “somatropin”, “Somatropin” and “PEG-somatropin”.
Its studies are mostly in Dwarfism, Pituitary · Turner Syndrome · Dwarfism · Growth Disorders · Genetic Diseases, Inborn, led by 15 companies.
Drug pageHuman Growth Hormone: every studyMany companies study it; this page follows only the 117 they lead. All 217 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 340 open or running | phase 4since Sep 13, 2005 | Feb 1, 2005 | none ahead |
| Changchun GeneScience Pharmaceutical | 194 open or running | phase 4since Nov 27, 2014 | Apr 21, 2011 | Apr 28, 2027phase 4 · NCT07691125 |
| Merck KGaA, Darmstadt, Germanyits history only | 190 open or running | phase 4since Nov 18, 2005 | May 13, 2004 | none ahead |
| Pfizerits history only | 180 open or running | phase 4since Feb 5, 2007 | Sep 9, 2005 | none ahead |
| Eli Lillyits history only | 100 open or running | phase 4since Dec 15, 2005 | Sep 12, 2005 | none ahead |
| LG Chemits history only | 40 open or running | phase 4since Nov 10, 2016 | Dec 29, 2005 | none ahead |
| Daewoong Pharmaceuticalits history only | 20 open or running | phase 3since Jan 19, 2016 | Sep 23, 2011 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Nov 7, 2005 | Nov 7, 2005 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Dec 4, 2014 | Mar 11, 2004 | none ahead |
| Ipsenits history only | 20 open or running | phase 4since Aug 24, 2011 | Oct 5, 2005 | none ahead |
| Altus Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Nov 28, 2011 | Nov 28, 2011 | none ahead |
| Clinique Ovoits history only | 10 open or running | phase 4since Oct 24, 2012 | Oct 24, 2012 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Mar 23, 2007 | Mar 23, 2007 | none ahead |
| Zhongshan Sansure Hygene Biomedicineits history only | 11 open or running | phase 3since Sep 2, 2026 | Sep 2, 2026 | Oct 2028phase 3 · NCT07815626 |
Also a collaborator on its studies: Merck Serono S.A.S, France, Merck Serono Co., Ltd., China, Merck Serono S.P.A., Italy, Merck Serono S.A., Geneva, Merck, S.L., Spain and BioPartners.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Changchun GeneScience Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Apr 21, 2011.
- Feb 1, 2015Phase 2 study in Short Stature Children Born Small for Gestational Age (SGA)NCT02375620 · 96 enrolled · China
- Mar 2, 2015Phase 4 study in Dwarfism, PituitaryNCT02380235 · 600 enrolled · China
- Sep 19, 2016Phase 4 study in Dwarfism, PituitaryNCT02908958 · 900 enrolled · China
- Nov 24, 2016Phase 4 study in Dwarfism, PituitaryNCT02976675 · 600 enrolled · China
- Mar 28, 2017Phase 2 study in Dwarfism, PituitaryNCT03104010 · 180 enrolled · China
- Jul 14, 20172 phase 2 studies in DwarfismNCT03255694, NCT03221088
- Jul 18, 2017Phase 3 study in Small for Gestational Age InfantNCT03245333 · 120 enrolled · China
- Jul 24, 2017Phase 4 study in Dwarfism, PituitaryNCT03249480 · 900 enrolled · China
- Sep 19, 2017Phase 4 study in Growth RetardationNCT03290235 · 1,500 enrolled · China
- Apr 28, 2018Phase 3 study in DwarfismNCT03535415 · 68 enrolled · China
- May 30, 2018Phase 3 study in Prader-Willi SyndromeNCT03554031 · 30 enrolled · China
- Jul 28, 2021Named human growth hormoneINNProposed as its International Nonproprietary Name in WHO's List 125
- Apr 25, 2022Phase 4 study in AchondroplasiaNCT05353192 · 39 enrolled · China
- Aug 9, 2023Phase 3 study in Dwarfism, PituitaryNCT06024967 · 180 planned
- Jul 1, 2026Phase 4 study in Short Bowel SyndromeNCT07691125 · 100 planned · China
Ahead
- Apr 28, 2027Primary completion: phase 4 study in Short Bowel SyndromeNCT07691125
- Jun 2030Primary completion: phase 2 study in DwarfismNCT03255694
TargetBeta
“Growth hormone receptor agonist”ChEMBL 37, by rule
Other programs on GHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lonapegsomatropinrule | ascendis-pharma-endocrinology-division-a-s | phase 3 | 6 |
Studies
All 19 Changchun GeneScience Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07691125Short Bowel Syndrome · China | 4 | Recruiting | Apr 28, 2027 | 100 |
| NCT06024967Dwarfism, Pituitary | 3 | Not yet recruiting | May 1, 2025 | 180 |
| NCT05353192Achondroplasia · China | 4 | Completed | Aug 25, 2025 | 39 |
| NCT03554031Prader-Willi Syndrome · China | 3 | UNKNOWN | Jan 2020 | 30 |
| NCT03535415Dwarfism · China | 3 | UNKNOWN | Sep 2020 | 68 |
| NCT03290235Growth Retardation · China | 4 | UNKNOWN | Oct 2020 | 1,500 |
| NCT03249480Dwarfism, Pituitary · China | 4 | UNKNOWN | Aug 2017 | 900 |
| NCT03245333Small for Gestational Age Infant · China | 3 | UNKNOWN | Dec 2017 | 120 |
| NCT03255694Dwarfism · China | 2 | Active, not recruiting | Jun 2030 | 360 |
| NCT03221088Dwarfism · China | 2 | UNKNOWN | Dec 2018 | 360 |
| NCT03104010Dwarfism, Pituitary · China | 2 | UNKNOWN | Feb 2022 | 180 |
| NCT02976675Dwarfism, Pituitary · China | 4 | UNKNOWN | Jun 2017 | 600 |
| NCT02908958Dwarfism, Pituitary · China | 4 | UNKNOWN | Jun 2017 | 900 |
| NCT02380235Dwarfism, Pituitary · China | 4 | UNKNOWN | Jun 2017 | 600 |
| NCT02375620Short Stature Children Born Small for Gestational Age (SGA) · China | 2 | Active, not recruiting | Dec 12, 2023 | 96 |
| NCT02314676Dwarfism, Pituitary · China | 4 | UNKNOWN | Jul 2017 | 900 |
| NCT01613573Dwarfism, Pituitary | 1 | Completed | Oct 2010 | 12 |
| NCT01495468Dwarfism, Pituitary · China | 3 | Completed | Jan 2008 | 343 |
| NCT01342146Dwarfism, Pituitary | 2 | Completed | Jan 2007 | 101 |
How it is read
Names in the registry
- “somatropin”, 52 entries
- “Somatropin”, 27 entries
- “PEG-somatropin”, 13 entries
- “Saizen®”, 6 entries
- “Genotropin”, 5 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 38 studies
- Turner Syndrome, 10 studies
- Dwarfism, 6 studies
- Growth Disorders, 4 studies
- Genetic Diseases, Inborn, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.